Please login to the form below
What does the Five Year Forward View mean for pharma?
Sue Thomas and Paul Midgley, of Wilmington Healthcare, assess how the Five Year Forward View (5YFV) is changing the NHS and how pharma can get involved in redesigning NHS services.
Introduction
to the 5YFV
When it was launched in October 2014, the
Five Year Forward View (5YFV) was hailed as one of the most
radical changes in the management and organisation of NHS England since its
inception in 1948.
Designed
by NHS England and five partner organisations, it aims to put an end to the
age-old divide between GPs with patients, and consultants with hospitals, and
develop new, integrated and cost efficient models of care that suit local
needs.
In
doing so, it aspires to create a sustainable NHS that continues to be funded by
the taxpayer, is free at the point of use and able to meet the evolving needs
of patients, now and in the future.
How can pharma capitalise on the 5YFV?
The 5YFV is dramatically changing the way that NHS services are run,
particularly at a local level. One of the biggest changes here is the planned
introduction of STPs – Sustainability and Transformation Plans – in 2017, which
will help to deliver 5YFV by
providing blueprints for delivering services locally.
Instead of taking a one-size
fits all approach to healthcare provision, STPs will see the commissioner/provider
split replaced by local planning and management within 44 areas across
England called ‘footprints’.
These area-specific, whole-system
plans will identify the health needs of their populations and define how
they should be addressed quickly and effectively at a local level.
Understanding
the bigger picture in terms of how STPs will affect areas such as NHS structure,
leadership, commissioning, KPIs, efficiency, procurement and patient pathways
is crucial for pharma. The industry also needs to get to grips with the
priorities and primary objectives of the individual 44 STPs.
Armed
with this knowledge, the
industry should look to offer tailored solutions that fit in with the
aspirations of individual STPs and will help them to fulfil the needs of their
local patient populations.
Sharing best practice – how can pharma help?
Sharing best practice is key
to accelerating the pace of change within the NHS and since October 2011, NHiS,
which is part of Wilmington Healthcare, has been helping to do this through its
Mental Health Commissioning Network conferences.
The events, which are being
sponsored this year by Lundbeck Ltd, Shire Ltd and Sunovion, bring like-minded
people together to discuss and exchange ideas on how to treat people with
mental health problems in a more integrated way. Wherever possible, they
involve locally identified Chairs plus the Strategic Clinical Networks,
Academic Health Science Networks and Public Health England. They provide an ideal opportunity for pharma
companies to get involved in shaping patient pathways and improving NHS
services in line with the objectives of 5YFV.
Conclusion
Since
its inception in 2014, 5YFV has been
dramatically changing the way that NHS services are run, particularly at local
level, and further major changes will occur when STPs are introduced next year.
In the midst of this upheaval, there are golden opportunities for pharma to get
involved in redesigning NHS services. The key is to keep abreast of the
changes, understand the bigger picture and find ways to utilise its expertise
to add value.
Sue
Thomas is CEO of the Commissioning Excellence Directorate and Paul Midgley is
director of NHS insight, both at Wilmington Healthcare.
www.wilmingtonhealthcare.com
Contact
Website
Address:
Beechwood House
2-3 Commercial Way
Christy Close
Southfields
Basildon
SS15 6EF
United Kingdom
- UNDERSTANDING THE ROLE OF PLACE WITHIN THE NEW NHS: FIVE THINGS INDUSTRY NEEDS TO KNOW
- Operating a level below system, “place” is an increasingly important unit of NHS organisation, yet it remains an evolving concept that is not always well-understood among industry practitioners. In this latest quick-read briefing, Oli Hudson, Content Director at Wilmington Healthcare, lifts the veil on what place is, how it works and why it matters.
Wilmington Healthcare
- MISSION CRITICAL: HOW PHARMA CAN HELP THE NHS IMPROVE CARE FOR OLDER PEOPLE
- With around two-thirds of all hospital beds occupied by over-65s, the care of older patients has long been recognised as key to the sustainability of the NHS. So how is it responding to this challenge, and what can industry do to support it? Oli Hudson, Content Director at Wilmington Healthcare, explains what’s changing and how industry should respond.
Wilmington Healthcare
- ALL CHANGE FOR SPECIALISED COMMISSIONING: FOUR THINGS INDUSTRY NEEDS TO KNOW ABOUT THE LATEST REFORMS
- With a recent NHSEI policy document confirming that a major shake-up of arrangements for Specialised Commissioning is imminent, Oli Hudson, Content Director at Wilmington Healthcare (wilmingtonhealthcare.com), describes the key changes and why they matter for pharma and med-tech companies.
Wilmington Healthcare
- HOW DID COVID-19 AFFECT PRESCRIBING BEHAVIOURS? FIVE KEY FINDINGS FROM A NEW STATE OF THE NATION REVIEW
- Published earlier this month, Wilmington Healthcare’s new State of the Nation report draws on a raft of data from across primary and secondary care to show what actually happened to the NHS and its prescribing behaviours during the peak of the pandemic. Oli Hudson summarises five of the key findings:
Wilmington Healthcare
- ALL SYSTEMS GO: UNDERSTANDING WHO’S WHO IN THE NEW NHS LANDSCAPE
- With the Health and Care Act safely passed, Oli Hudson introduces six key stakeholders that will loom large in the new landscape.
Wilmington Healthcare
- Spending on anti-depressants soars as the pandemic’s effect on NHS prescribing patterns is revealed
Wilmington Healthcare